Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Zanidatamab as Second-Line Therapy in HER2-Positive Advanced Gastric Cancer (K-Umbrella)
KCT0007067Phase 2Active, not recruiting
- Sponsor
- BeiGene
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, zanidatamab in gastric cancer (GC), sponsored by BeiGene. Started Sep 2022; status: active, not recruiting.
02
Drugs
tislelizumabzanidatamab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0007067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007067.